Goldman Sachs’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-494,248
| Closed | -$47.9M | – | 5530 |
|
|
2019
Q3 | $47.9M | Sell |
494,248
-61,546
| -11% | -$6.16M | 0.01% | 1131 |
|
|
2019
Q2 | $56.9M | Sell |
555,794
-580,300
| -51% | -$62.6M | 0.02% | 1057 |
|
|
2019
Q1 | $129M | Buy |
1,136,094
+303,081
| +36% | +$22.3M | 0.04% | 526 |
|
|
2018
Q4 | $32.6M | Buy |
833,013
+386,635
| +87% | +$16.8M | 0.01% | 1418 |
|
|
2018
Q3 | $24.4M | Buy |
446,378
+150,068
| +51% | +$10.3M | 0.01% | 1779 |
|
|
2018
Q2 | $24.5M | Buy |
296,310
+171,777
| +138% | +$13.3M | 0.01% | 1727 |
|
|
2018
Q1 | $8.29M | Sell |
124,533
-230,839
| -65% | -$13.3M | ﹤0.01% | 2496 |
|
|
2017
Q4 | $18.3M | Sell |
355,372
-218,826
| -38% | -$15.7M | ﹤0.01% | 2002 |
|
|
2017
Q3 | $51.2M | Sell |
574,198
-46,439
| -7% | -$3.53M | 0.01% | 1269 |
|
|
2017
Q2 | $37.1M | Buy |
620,637
+70,576
| +13% | +$3.94M | 0.01% | 1453 |
|
|
2017
Q1 | $29.3M | Buy |
550,061
+51,954
| +10% | +$3.08M | 0.01% | 1611 |
|
|
2016
Q4 | $24.9M | Buy |
498,107
+19,160
| +4% | +$1.03M | 0.01% | 1811 |
|
|
2016
Q3 | $28.8M | Buy |
478,947
+140,495
| +42% | +$8.1M | 0.01% | 1632 |
|
|
2016
Q2 | $17.3M | Buy |
338,452
+281,187
| +491% | +$12M | 0.01% | 1894 |
|
|
2016
Q1 | $1.69M | Buy |
57,265
+52,510
| +1,104% | +$1.66M | ﹤0.01% | 3639 |
|
|
2015
Q4 | $215K | Buy |
4,755
+3,389
| +248% | +$178K | ﹤0.01% | 5643 |
|
|
2015
Q3 | $57K | Sell |
1,366
-9,132
| -87% | -$477K | ﹤0.01% | 6745 |
|
|
2015
Q2 | $633K | Sell |
10,498
-1,098
| -9% | -$72.6K | ﹤0.01% | 4948 |
|
|
2015
Q1 | $899K | Buy |
+11,596
| New | +$668K | ﹤0.01% | 4578 |
|
Goldman Sachs's ONCE Position: Q4 2019 in Review
Goldman Sachs sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 494,248 shares — an estimated $47.9M sold.
Goldman Sachs first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $129M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Goldman Sachs reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Goldman Sachs sold 494,248 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $47.9M.
- Goldman Sachs first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Goldman Sachs's Spark Therapeutics, Inc. Common Stock position peaked at $129M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.